![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 25, 2007 10:19:10 AM
Wednesday April 25, 7:00 am ET
By Karen Andersen
Pharmaceutical companies still see riches in biotechnology. AstraZeneca's (NYSE:AZN - News) $15.6 billion deal to acquire MedImmune (NasdaqGS:MEDI - News) is only the latest example of their continuing willingness to pay high premiums (in this case, a 53% premium to where MedImmune was trading before it put itself up for sale) for future growth.
At Morningstar, we've seen various themes to these drug stock take-outs over the past year. In some cases, the larger firm in a collaboration takes out the smaller partner, in an effort to claim full rights to future profits; Amgen's (NasdaqGS:AMGN - News) acquisition of antibody expert Abgenix and Lilly's (NYSE:LLY - News) acquisition of Cialis-driven ICOS are both good examples of this behavior. Sometimes a firm looks to expand into new therapeutic areas, such as when HIV expert Gilead (NasdaqGS:GILD - News) bought cardiopulmonary firm Myogen, Merck (NYSE:MRK - News) bought Sirna Therapeutics for its innovative new RNA interference technology, or when Abbott (NYSE:ABT - News) bought Kos Pharmaceuticals for its cholesterol drug pipeline. In other cases, firms attempt to ward off slowing growth by injecting new products into established businesses, like Genzyme's (NasdaqGS:GENZ - News) purchase of AnorMED to supplement a sluggish transplant segment, or Shire's (Other OTC:SHPGF.PK - News) purchase of New River to fend off generic competition to its attention deficit franchise.
Given the current interest in scooping up biotechs at healthy prices, we've decided to use clues from past acquisitions to provide a list of firms that represent potential future targets. To start, we've created a screen that filters out any biotechs with market capitalizations of less than $250 million (firms that tend to be extremely volatile and speculative) and greater than $15 billion (firms that are difficult for even large pharmaceutical companies to afford). We've also screened for biotechs that we don't think are overvalued by the market--that is, firms that have received a Morningstar Rating of at least 3 stars. We were left with 26 firms, which we've qualitatively culled into a list of what we see as the five most likely future targets, as shown in the table below.
To see the related table, click here:
http://news.morningstar.com/article/article.asp?id=190410
As we discussed in our most recent quarterly review of the health-care sector, we don't typically factor acquisition speculation into our fair value estimates, but instead focus on what we think the firm's products and pipeline are really worth in the long run. Below, we've highlighted why we think these five firms could create value for prospective buyers, including excerpts from company reports.
...
BioMarin Pharmaceutical (NasdaqGM:BMRN - News)
BioMarin's rare disease expertise has earned it a narrow economic moat, and strong prospects for current products and its late-stage pipeline could make it a desirable target for partner Genzyme or other firms looking to gain exposure to this niche. While share prices fell in February due to poor hypertension data for lead pipeline candidate Phenoptin, we still think the drug has excellent prospects to treat the rare disease phenylketonuria, and it could be on the market by the end of the year. As I mention in my analysis, "BioMarin should enjoy steady sales growth from its innovative, life-saving treatments, and we expect it is just a matter of time before this biotech turns a profit."
Recent BMRN News
- BioMarin Announces New R&D and Business Development Leadership • PR Newswire (US) • 08/21/2024 12:30:00 PM
- BioMarin to Host 2024 Investor Day on September 4th in New York • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 07:57:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 03:48:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:35:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:28 PM
- BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance • PR Newswire (US) • 08/05/2024 08:03:00 PM
- BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy • PR Newswire (US) • 08/05/2024 08:01:00 PM
- U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease • PR Newswire (US) • 07/24/2024 08:05:00 PM
- BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET • PR Newswire (US) • 07/23/2024 12:00:00 PM
- BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health • PR Newswire (US) • 06/17/2024 12:30:00 PM
- KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 • PR Newswire (US) • 06/07/2024 10:09:00 PM
- BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress • PR Newswire (US) • 06/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 11:28:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/04/2024 02:18:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:28:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/31/2024 02:49:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:18:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 06:22:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 02:18:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 02:10:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 02:28:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 02:36:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:02:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:36:34 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM